Published in Nat Rev Drug Discov on February 03, 2012
Autologous Dendritic Cell Vaccination in Mesothelioma (MESODEC) | NCT02649829
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2013) 1.64
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ (2013) 1.60
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2013) 1.42
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. Oncoimmunology (2014) 1.35
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 1.21
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Cytokine-induced killer cells promote antitumor immunity. J Transl Med (2013) 1.16
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15
Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol (2013) 1.14
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer (2014) 1.07
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep (2014) 1.04
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep (2016) 1.03
Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res (2014) 1.03
A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst (2014) 1.02
ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology (2013) 1.01
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol (2012) 1.00
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett (2014) 1.00
Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 1.00
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene (2014) 0.97
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm (2014) 0.95
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology (2012) 0.94
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology (2013) 0.93
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
Current trends of anticancer immunochemotherapy. Oncoimmunology (2013) 0.91
Victories and deceptions in tumor immunology: Stimuvax(®) Oncoimmunology (2013) 0.91
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology (2012) 0.91
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? Breast Care (Basel) (2012) 0.90
Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int J Mol Sci (2013) 0.90
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J (2014) 0.89
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Immune effectors required for the therapeutic activity of vorinostat. Oncoimmunology (2013) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol (2013) 0.89
Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 0.88
Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology (2013) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
New generation of dendritic cell vaccines. Hum Vaccin Immunother (2013) 0.86
Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86
Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl) (2015) 0.86
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85
Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. Mol Cancer Ther (2014) 0.85
Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) (2013) 0.85
Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality. Mol Ther (2013) 0.84
Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology (2014) 0.84
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol (2006) 6.38
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov (2002) 6.13
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature (1979) 5.75
How the glucocorticoids suppress immunity. Science (1995) 5.74
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature (1980) 5.22
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer (2005) 4.16
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 3.53
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood (2007) 3.13
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer (2007) 2.87
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 2.49
Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev (2005) 2.42
The role of PI3K in immune cells. Nat Immunol (2003) 2.41
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab (2009) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med (2010) 2.07
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother (2011) 1.93
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer (2006) 1.91
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother (2010) 1.89
CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res (2011) 1.89
The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol (2005) 1.89
A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res (2010) 1.89
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47
The hallmarks of aging. Cell (2013) 14.29
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Autophagy and aging. Cell (2011) 5.96
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Does autophagy contribute to cell death? Autophagy (2005) 3.21
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56
Autophagy regulation by p53. Curr Opin Cell Biol (2010) 2.56
Can autophagy promote longevity? Nat Cell Biol (2010) 2.55
Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51
Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Fatty acids trigger mitochondrion-dependent necrosis. Cell Cycle (2010) 2.37
Complex inhibitory effects of nitric oxide on autophagy. Mol Cell (2011) 2.36
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
An AIF orthologue regulates apoptosis in yeast. J Cell Biol (2004) 2.33
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol (2012) 2.28
miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24
Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23
Viral control of mitochondrial apoptosis. PLoS Pathog (2008) 2.21
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell (2012) 2.14